Day One Biopharmaceuticals, Inc.
Clinical trials sponsored by Day One Biopharmaceuticals, Inc., explained in plain language.
-
Experimental HER2 cancer drug trial halted early
Disease control TerminatedThis was an early-phase study testing a new drug called XMT-2056 in people with advanced solid tumors that have a protein called HER2. The trial aimed to find a safe dose and check for side effects. It was terminated early, so the full results are not available.
Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets genetic weakness in tough cancers
Disease control TerminatedThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC